Levi & Korsinsky Initiates Class Action Against Cerevel Therapeutics Holdings, Inc. for Shareholders' Rights
On April 22, 2025, Levi & Korsinsky, LLP announced the initiation of a securities class action lawsuit on behalf of investors in Cerevel Therapeutics Holdings, Inc., traded under the symbol ABBV. This legal action arises from assertions of securities fraud that have adversely impacted shareholders. The lawsuit specifically targets those who held or traded shares during the period from October 11, 2023, to August 1, 2024.
The complaint under scrutiny points to a significant stock offering by Cerevel on October 16, 2023. It alleges that the documents and public statements associated with this offering failed to disclose crucial information about AbbVie's intentions concerning a potential acquisition of Cerevel at a price significantly higher than the offering price of $22.81 per share. These omissions purportedly caused the stock price to be artificially suppressed until the announcement of a merger.
Bain Capital Investors, LLC, the majority shareholder of Cerevel, allegedly acquired shares at this reduced price while possessing nonpublic information about the impending acquisition. Subsequently, AbbVie announced its agreement to purchase Cerevel at $45 per share on December 6, 2023. This resulted in Bain recognizing substantial profits exceeding $120 million from their holdings purchased at the depressed prices.
Cerevel's Proxy statement on January 18, 2024, is also under scrutiny for allegedly misleading investors about the timing and nature of AbbVie's interest. Investors whose financial positions were impacted during this timeline have until June 3, 2025, to rally for appointment as lead plaintiff in the case. Importantly, participation as a class member carries no out-of-pocket costs, and compensation may be available without the need to serve as a lead plaintiff.
Levi & Korsinsky has established a commendable reputation over the last two decades, securing hundreds of millions in compensation for investors across numerous high-profile cases. They are known for their prowess in handling intricate securities litigation, boasting a dedicated team of over 70 professionals committed to supporting their clients. Consistently rated among the top securities litigation firms by ISS Securities Class Action Services, Levi & Korsinsky provides a robust platform for investors seeking justice.
To further explore your rights and get assistance regarding the lawsuit, interested parties may reach out to Levi & Korsinsky via email or phone. For those affected, understanding the developments in this case is essential for safeguarding your investments and ensuring accountability from corporate entities.
The filing from Levi & Korsinsky signals an important step for shareholders of Cerevel Therapeutics Holdings, Inc. in addressing alleged misconduct. It's a reminder of the vigilance required in the investment landscape and the necessity of ethical practices in corporate governance. As this case unfolds, investors are encouraged to stay informed and consider their options in light of the potential implications.
Case Overview
The complaint under scrutiny points to a significant stock offering by Cerevel on October 16, 2023. It alleges that the documents and public statements associated with this offering failed to disclose crucial information about AbbVie's intentions concerning a potential acquisition of Cerevel at a price significantly higher than the offering price of $22.81 per share. These omissions purportedly caused the stock price to be artificially suppressed until the announcement of a merger.
Bain Capital Investors, LLC, the majority shareholder of Cerevel, allegedly acquired shares at this reduced price while possessing nonpublic information about the impending acquisition. Subsequently, AbbVie announced its agreement to purchase Cerevel at $45 per share on December 6, 2023. This resulted in Bain recognizing substantial profits exceeding $120 million from their holdings purchased at the depressed prices.
What Investors Should Know
Cerevel's Proxy statement on January 18, 2024, is also under scrutiny for allegedly misleading investors about the timing and nature of AbbVie's interest. Investors whose financial positions were impacted during this timeline have until June 3, 2025, to rally for appointment as lead plaintiff in the case. Importantly, participation as a class member carries no out-of-pocket costs, and compensation may be available without the need to serve as a lead plaintiff.
Why Choose Levi & Korsinsky?
Levi & Korsinsky has established a commendable reputation over the last two decades, securing hundreds of millions in compensation for investors across numerous high-profile cases. They are known for their prowess in handling intricate securities litigation, boasting a dedicated team of over 70 professionals committed to supporting their clients. Consistently rated among the top securities litigation firms by ISS Securities Class Action Services, Levi & Korsinsky provides a robust platform for investors seeking justice.
To further explore your rights and get assistance regarding the lawsuit, interested parties may reach out to Levi & Korsinsky via email or phone. For those affected, understanding the developments in this case is essential for safeguarding your investments and ensuring accountability from corporate entities.
Conclusion
The filing from Levi & Korsinsky signals an important step for shareholders of Cerevel Therapeutics Holdings, Inc. in addressing alleged misconduct. It's a reminder of the vigilance required in the investment landscape and the necessity of ethical practices in corporate governance. As this case unfolds, investors are encouraged to stay informed and consider their options in light of the potential implications.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.